Do you have conjunctivitis, commonly referred to as ‘pink eye’?
We are researching the use of a new medicine intended to treat conjunctivitis ‘pink eye’. This experimental medicine is intended to treat both the infectious and the inflammatory components of conjunctivitis, allowing resolution of the symptoms.
We are currently recruiting study participants who:
- Are adults or children of any age.
- Have signs, symptoms, or a diagnosis of adenoviral or bacterial conjunctivitis in either eye that began within the past 4 days.
Key signs and symptoms of conjunctivitis (in one or both eyes) include:
- White or yellow discharge
Participants will need to attend five clinic visits over a 13-day period.
To see if you are eligible complete the questionnaire or call the Clinical Trials Centre on 07 5456 3797.
Full title: SHP640-301 A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to PVP-Iodine and Placebo in the Treatment of Adenoviral Conjunctivitis.
SHP640-303 A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to Placebo in the Treatment of Bacterial Conjunctivitis.
Ethics approval – Bellberry Limited
If you experience difficulty completing the survey please email email@example.com
H2 Vision Centre
7/11 Chancellor Village Blvd
SIPPY DOWNS QLD 4556